Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | active not recruiting | Phase 1 | 169 | IDEAYA BiosciencesINDUSTRY | 7 | Apr 9, 2026 | clinicaltrials |
| NCT05178472 | Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria) | recruiting | N/A | 200 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06305884 | Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study | completed | N/A | 76 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07192107 | A Study of MHB042C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07192120 | A Study of MHB048C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03361436 | Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | active not recruiting | Phase 1 | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04420884 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors(iintune-1) | completed | Phase 1 / Phase 2 | 248 | TakedaINDUSTRY | 11 | Apr 8, 2026 | clinicaltrials |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | terminated | Phase 1 | 91 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05262530 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | terminated | Phase 1 / Phase 2 | 73 | BioNTech SEINDUSTRY | 4 | Apr 8, 2026 | clinicaltrials |
| NCT07225920 | Understanding Needs of Older Patients Prior to Starting Cancer Treatment(PGA) | enrolling by invitation | N/A | 216 | Wake Forest University Health SciencesOTHER | 2 | Apr 8, 2026 | clinicaltrials |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer(MUIR) | recruiting | Phase 1 | 172 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 7 | Apr 7, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT06008392 | INTERogating Cancer for Etiology, Prevention and Therapy Navigation(INTERCEPTioN) | recruiting | — | 500 | Mayo ClinicOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06911827 | A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 149 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT00736749 | Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | active not recruiting | — | 5,000 | Children's Oncology GroupNETWORK | 2 | Apr 6, 2026 | clinicaltrials |
| NCT04983901 | PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05785741 | A Study of DB-1310 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,000 | DualityBio Inc.INDUSTRY | 2 | Apr 6, 2026 | clinicaltrials |
| NCT05873608 | Communication Issues in Patient and Provider Discussions of Immunotherapy | recruiting | N/A | 125 | Emory UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06306638 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction | recruiting | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06773091 | A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors(NKSOLID) | recruiting | Phase 1 | 76 | Shanghai NK Cell Technology Co., LTDINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510841 | JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR | not yet recruiting | Phase 1 / Phase 2 | 228 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT02937272 | A Study of LY3200882 in Participants With Solid Tumors | active not recruiting | Phase 1 | 223 | Eli Lilly and CompanyINDUSTRY | 8 | Apr 3, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04911907 | Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors | completed | Phase 2 | 126 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04931823 | Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 34 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05752552 | Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours | recruiting | Phase 1 | 55 | DeuterOncologyINDUSTRY | 3 | Apr 3, 2026 | clinicaltrials |
| NCT07446153 | A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects | recruiting | Phase 1 / Phase 2 | 282 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07510321 | FL-261 Imaging for Cancer Diagnosis and Staging | recruiting | — | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04475640 | Cancer Genetic Testing in Ethnic Populations | recruiting | N/A | 1,800 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT07221409 | Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment | recruiting | N/A | 24 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02457962 | Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study | recruiting | — | 15,000 | Mayo ClinicOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04050709 | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | completed | Phase 1 | 16 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05148325 | Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors | completed | Phase 1 | 28 | Bio-Thera SolutionsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01) | recruiting | Phase 1 / Phase 2 | 150 | Incyclix BioINDUSTRY | 2 | Apr 1, 2026 | clinicaltrials |
| NCT05773820 | A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 210 | Wigen Biomedicine Technology (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06915727 | An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors | recruiting | Phase 3 | 20 | Mayo ClinicOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505069 | Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors | recruiting | Early Phase 1 | 10 | Nanolattix Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02133625 | A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05223608 | Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy(ImmuCCo) | recruiting | N/A | 651 | Centre Oscar LambretOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06395441 | Wisconsin Ginseng for Decreasing Cancer Related Fatigue | recruiting | Phase 3 | 160 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06770569 | A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors | recruiting | Phase 1 | 100 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT06805461 | PumaRx Registry Trial(PumaRx) | recruiting | — | 1,000 | RenovoRxINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07089927 | Virtual Art Therapy Assisted Re-Integration to Improve Biopsychosocial Outcomes in Adolescent and Young Adult Cancer Survivors, AVATARS Trial | recruiting | N/A | 30 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT00477958 | Assessment Tool for Older Patients With Cancer | active not recruiting | N/A | 1,062 | City of Hope Medical CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR) | recruiting | Phase 2 | 720 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05982522 | IN10018 Combination Therapy in Previously-treated Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 0 | Mar 27, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 9, 2026source: clinicaltrials